Biotechnology company developing antibody-based therapies for cancer.
MacroGenics, Inc. is a prominent biopharmaceutical company based in Rockville, Maryland, specializing in the development and commercialization of antibody-based therapeutics for the treatment of cancer in the United States. The company's flagship product, MARGENZA (margetuximab-cmkb), is a human epidermal growth factor receptor 2 (HER2) antagonist approved for use in combination with chemotherapy. It is indicated for adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens.
MacroGenics maintains a robust pipeline of immuno-oncology product candidates aimed at addressing various solid tumors and hematologic malignancies. These include MGC018, an antibody-drug conjugate (ADC) targeting B7-H3 in solid tumors, and Enoblituzumab, a monoclonal antibody also targeting B7-H3. Additionally, the company is advancing MGD024, a bispecific CD123 × CD3 DART molecule designed to mitigate cytokine-release syndrome in patients with hematologic cancers.
Further expanding its therapeutic portfolio, MacroGenics is developing Lorigerlimab, a monoclonal antibody targeting immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), along with Tebotelimab, an investigational tetravalent DART molecule targeting PD-1 and lymphocyte-activation gene 3 (LAG-3). The company's innovative approach extends to therapies like Retifanlimab, a monoclonal antibody for treating metastatic squamous cell carcinoma of the anal canal and non-small cell lung cancer.
MacroGenics collaborates with leading biopharmaceutical firms including Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech, Inc., to leverage its cutting-edge technology platforms and enhance the development of novel therapeutics. Founded in 2000, MacroGenics continues to advance its mission of pioneering new treatments that address significant unmet medical needs in oncology and beyond.